CapsoVision (CV) vs EDAP TMS S.A. (FOCL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
EDAP TMS S.A. (FOCL) has outperformed CapsoVision (CV) over the past year, gaining 86.7% versus a gain of 43.9%. CapsoVision is the larger company by market cap ($350.7 million vs $197.8 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CV | FOCL |
|---|---|---|
| Share price | $6.59 | $4.19 |
| Market cap | $350.66M | $197.84M |
| 1-day change | -0.45% | +1.58% |
| YTD return | -38.07% | +25.38% |
| 1-year return | +43.91% | +86.65% |
| 5-year return | — | -31.82% |
| EPS (TTM) | $-0.45 | $-1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.37 | $6.40 |
| 52-week low | $4.38 | $1.75 |
| Distance from 52-week high | -57.12% | -34.53% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +44.16% | +110.02% |
| Average volume | 157.18K | 114.80K |
| Shares outstanding | 53.21M | 47.22M |
| Employees | 99 | 289 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FOCL has outperformed CV by 42.7 percentage points over the past year.
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees
About EDAP TMS S.A.
FOCL stock →EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 289 employees
CV vs FOCL FAQ
Which is bigger, CapsoVision or EDAP TMS S.A.?
CapsoVision (CV) is larger, with a market capitalization of $350.66M compared with $197.84M for EDAP TMS S.A. (FOCL).
Which stock has performed better over the past year, CV or FOCL?
FOCL returned +86.65% over the past 12 months, compared with +43.91% for CV (price return, excluding dividends). Past performance does not predict future results.
Are CapsoVision and EDAP TMS S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.